Clinical trial
The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris
NCT01088165 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris
- Lead sponsor
- Medical University of Vienna
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- May 31, 2010
- Completion date
- May 31, 2014
- Enrollment
- 66 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.